CPDC Celebrates Successful FDA Inspection!

August 23, 2019 CPDC
« 1 of 6 »

Hamilton, Ontario, August 16, 2019 – The Centre for Probe Development and Commercialization’s Senior Leadership Team took time on Friday afternoon to celebrate with their Hamilton staff on the McMaster University campus at the famous Willy Dog Hot Dog cart. Over 60 staff attended the lunch time event on a great summer day!  The event was held to show appreciation to our staff for the effort put into the preparation for CPDC’s FDA audit held in July 2019. Special treats were sent to our offsite locations in Toronto and Ottawa, as well as to the night shift staff in Hamilton, to ensure the whole company was included in the event.

CPDC’s President and CEO, Dr. Joe McCann commented at the event that “CPDC is committed to maintaining industry leading quality standards and implementing continued quality improvements. We are very grateful and appreciative of our staff who all embrace this approach and who put significant effort into the preparation for the audit.  We are extremely pleased to announce that no observations were received at the conclusion of the inspection.  CPDC extends its gratitude to our clients who supported us during the inspection.” CPDC is also inspected by Health Canada and has maintained a compliant rating since 2009.

About CPDC

The Centre for Probe Development and Commercialization (CPDC) is a private, not-for-profit company “Dedicated to improving patient’s lives by advancing drugs for the diagnosis and treatment of diseases.”  Created in 2008, with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute for Cancer Research (OICR), CPDC has become a global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals. With an established a pipeline of products and a robust and reliable manufacturing unit, CPDC supplies innovative diagnostic and therapeutic radiopharmaceuticals that are used daily in Canada and around the world. CPDC currently employs over 110 staff in Hamilton, Toronto and Ottawa. For more information about CPDC, please visit: www.imagingprobes.ca

Contacts

Centre for Probe Development and Commercialization

Angela Lauretani, 905 525-9140, ext. 21212

cpdc@imagingprobes.ca

More news from CPDC

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

Hamilton, Ontario, February 24, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that

CARI Blog #2: Discover the Medical Isotope & Radiopharmaceutical Landscape in Canada

Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people are unaware of Canadian role in this industry. However, several medical applications that are used widely today stemmed from Canadian nuclear isotope programs where much

POINT Biopharma signs exclusive license agreement with CanProbe for the commercialization of a neuroendocrine tumor treatment

January 12th, 2021 – TORONTO, CANADA – POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer.

For more information contact us at: